These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23006045)

  • 21. A note on post-marketing safety study design to characterise time-dependent adverse events.
    Narukawa M; Yafune A
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1146-52. PubMed ID: 17803255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some key points emerging from the COX-2 controversy.
    Urquhart J
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723
    [No Abstract]   [Full Text] [Related]  

  • 23. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data.
    Rolka H; Bracy D; Russell C; Fram D; Ball R
    Stat Med; 2005 Feb; 24(4):551-62. PubMed ID: 15678409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Vioxx debacle revisited.
    Daikh DI
    Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
    [No Abstract]   [Full Text] [Related]  

  • 25. A conditional maximized sequential probability ratio test for pharmacovigilance.
    Li L; Kulldorff M
    Stat Med; 2010 Jan; 29(2):284-95. PubMed ID: 19941282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of epidemiologic methods for active surveillance of vaccine safety.
    McClure DL; Glanz JM; Xu S; Hambidge SJ; Mullooly JP; Baggs J
    Vaccine; 2008 Jun; 26(26):3341-5. PubMed ID: 18462849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM; Lévesque LE; Zhang B
    Heart; 2007 Feb; 93(2):189-94. PubMed ID: 16849374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 30. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 31. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Couzin J
    Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lessons of Vioxx.
    Weinberg JM
    Cutis; 2005 Jan; 75(1):17. PubMed ID: 15732429
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parametric conditional frailty models for recurrent cardiovascular events in the lipid study.
    Cui J; Forbes A; Kirby A; Marschner I; Simes J; West M; Tonkin A
    Clin Trials; 2008; 5(6):565-74. PubMed ID: 19029205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marginal regression models with time-varying coefficients for recurrent event data.
    Sun L; Zhou X; Guo S
    Stat Med; 2011 Aug; 30(18):2265-77. PubMed ID: 21590791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
    Mahabaleshwarkar RK; Yang Y; Datar MV; Bentley JP; Strum MW; Banahan BF; Null KD
    Curr Med Res Opin; 2013 Apr; 29(4):315-23. PubMed ID: 23362935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.